You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Aerosol Sampling and Microfluidic Analysis of Reactive Oxygen Species
SBC: ILLIONIX, LLC Topic: 113DESCRIPTION provided by applicant Cardiovascular diseases and Asthma affects between and million people in the United States including million children during the past years its incidence worldwide has doubled Asthma is responsible for million person days of restricted activity and deaths per year amounting to $ billion in direct heath related costs there is uncertainty about the specific factors ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes
SBC: CUMBERLAND PHARMACEUTICALS, INC. Topic: 300DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Sparse-readout Quantitative PET scanner for breast cancer therapy optimization
SBC: PET/X LLC Topic: 102The goal of this project is to develop a quantitative molecular breast imaging PET QMBI PET scanner to improve the way in which breast cancer therapies are matched to individual patients by providing evaluation of therapy efficacy during the window of opportunity between diagnosis and surgical resection More than women in the US with invasive disease start therapy for breast cancer each ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Clonotyping Technology for Prediction of Antibiotic Resistance
SBC: ID GENOMICS SPC Topic: NIAIDDESCRIPTIONprovided by applicantThe primary goal of this proposal is to develop and finalize configuration of a rapid molecular diagnostics test to predict antibiotic resistance of th major human uropathogensEscherichia coliKlebsiella pneumoniaeEnterobacter spp and Pmirabilisby determining the sub species clonal identityclonotypeof the infecting bacteria directly from urine samplesCurrentlythe emp ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Innovative Mitigation of Radiation Effects in Advanced Technology Nodes
SBC: RELIABLE MICROSYSTEMS LLC Topic: DTRA16A003Establish a radiation-aware analysis capability in a commercial EDA design flow that will enable first-pass success in radiation-hardened by design (RHBD) for DoD ASICs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications. Layout-aware, calibrated single-event radiation models that captur ...
STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency -
Microfluidic Platform for Stem Cell Applications
SBC: Nortis, Inc. Topic: NCATSDESCRIPTION provided by applicant The emerging field of stem cell therapy has the potential to transform medicine forever However a major bottleneck for bringing stem cell therapies to the patient is the lack of adequate in vitro assays for the study of stem cell quality Critical test criteria are efficacy pluripotency prior to the differentiation process and safety lack of tumorigenicity ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Optimization of a computationally designed antiviral for influenza
SBC: Virvio Inc Topic: NIAIDDESCRIPTION provided by applicant Influenza is a leading cause of death and morbidity in the US resulting in up to deaths hospitalizations and andgt $ billion in expenses per year Current antivirals incur high resistance rates and have low efficacy so there is a crucial need to develop better approaches to protect from seasonal influenza and future pandemics We aim to ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Optimization of a novel cancer immunotherapeutic antibody for human use
SBC: CANCURE LLC Topic: 102ABSTRACT The goal of this application is to evaluate the cancer therapeutic feasibility of CanCureandapos s humanized first in class immunostimulatory monoclonal antibody mAb huB G the Product also names CuraB During cancer development in response to oncogenic insult or stress almost ALL human cancer cells are induced to express a SURFACE molecule MIC MHC I chain related Molecule wh ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Optimization of Pre- and Post-Operative Pain Management
SBC: CHANGE MANAGEMENT CONSULTING, LLC Topic: NIDAAbstract Despite joint replacement surgeries becoming an increasingly common surgical procedure uncontrolled post operative pain is a major cause of patient suffering and dissatisfaction and leads to chronic pain Development of chronic post surgical pain often treated with opioids is frequent and recognized as a major clinical problem Persistent opioid use due to uncontrolled chronic pain is ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Potential of the Potassium Channel Inhibitor SHK-186 for Pediatric Lupus
SBC: KINETA, INC. Topic: RDESCRIPTION provided by applicant Systemic lupus erythematosus SLE is a chronic multisystem autoimmune disease with poorly understood etiology and pathogenesis and for which adequate treatment options are limited Although dysregulated production of autoantibodies and immune complex deposition are considered hallmarks of SLE considerable evidence supports the hypothesis that auto reactive ly ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health